Advertisement
UK markets closed

  • FTSE 100

    8,139.83
    +60.97 (+0.75%)
     

  • FTSE 250

    19,824.16
    +222.18 (+1.13%)
     

  • AIM

    755.28
    +2.16 (+0.29%)
     

  • GBP/EUR

    1.1681
    +0.0025 (+0.21%)
     

  • GBP/USD

    1.2497
    -0.0014 (-0.11%)
     

  • Bitcoin GBP

    51,260.92
    -486.86 (-0.94%)
     

  • CMC Crypto 200

    1,332.51
    -64.03 (-4.58%)
     

  • S&P 500

    5,109.10
    +60.68 (+1.20%)
     

  • DOW

    38,322.06
    +236.26 (+0.62%)
     

  • CRUDE OIL

    83.95
    +0.38 (+0.45%)
     

  • GOLD FUTURES

    2,349.90
    +7.40 (+0.32%)
     

  • NIKKEI 225

    37,934.76
    +306.28 (+0.81%)
     

  • HANG SENG

    17,651.15
    +366.61 (+2.12%)
     

  • DAX

    18,161.01
    +243.73 (+1.36%)
     

  • CAC 40

    8,088.24
    +71.59 (+0.89%)
     
PROPERTY:

9 luxury homes to consider if money is no object

Ever thought about what a multimillion pound budget would buy you?

Why Atea Pharmaceuticals Stock Got Crushed This Week

George Budwell, The Motley Fool
·2-min read
Why Atea Pharmaceuticals Stock Got Crushed This Week

Shares of the clinical-stage biotech Atea Pharmaceuticals (NASDAQ: AVIR) closed the week down by a whopping 68.6%, according to data from S&P Global Market Intelligence. The biotech's stock plummeted last Tuesday after announcing that its oral antiviral pill, known as AT-527, badly missed the mark in a phase 2 trial called MOONSONG for patients with mild or moderate cases of COVID-19. AT-527 is being co-developed with pharma heavyweight Roche (OTC: RHHBY).

Continue reading